{"id":6188,"date":"2026-02-09T09:13:06","date_gmt":"2026-02-09T09:13:06","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/6188\/"},"modified":"2026-02-09T09:13:06","modified_gmt":"2026-02-09T09:13:06","slug":"novo-nordisk-stock-jumps-over-8-after-rival-hims-hers-withdraws-knockoff-weight-loss-drug-amid-regulatory-scrutiny","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/6188\/","title":{"rendered":"Novo Nordisk stock jumps over 8% after rival Hims & Hers withdraws knockoff weight-loss drug amid regulatory scrutiny"},"content":{"rendered":"

Denmark-based pharmaceutical giant, Novo Nordisk, stock surged more than 8% during the intraday trading session on Monday, 9 February 2026, after rival healthcare firm Hims & Hers withdrew its knockoff weight-loss drug from the market amid regulatory scrutiny from the US federal government. <\/p>\n

Novo Nordisk stock jumped 8.6% to 321 Danish Krone (kr) during the trading session on Monday, compared to 295.50 kr at the previous stock market close, according to MarketWatch data. <\/p>\n

\u201cSince launching the compounded semaglutide pill on our platform, we\u2019ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us for access to safe, affordable, and personalised care,\u201d said Hims & Hers in a recent post on platform X. <\/p>\n

(This is a developing story. Please check back for updates.)<\/p>\n

Read all stories by Anubhav Mukherjee<\/a><\/p>\n

Disclaimer: This story is for educational purposes only. We advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and circumstances may vary. <\/p>\n","protected":false},"excerpt":{"rendered":"Denmark-based pharmaceutical giant, Novo Nordisk, stock surged more than 8% during the intraday trading session on Monday, 9…\n","protected":false},"author":2,"featured_media":6189,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[1440,272,5490,5487,5488,5489,5485,5486,5484,3388],"class_list":{"0":"post-6188","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-hims-hers","9":"tag-novo-nordisk","10":"tag-novo-nordisk-shares","11":"tag-novo-nordisk-stock","12":"tag-novo-nordisk-stock-price","13":"tag-novo-stock","14":"tag-regulatory-scrutiny","15":"tag-stock-market-news","16":"tag-stock-surge","17":"tag-weight-loss-drug"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/6188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=6188"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/6188\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/6189"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=6188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=6188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=6188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}